The Platelet-to-Lymphocyte Ratio Is an Independent Prognostic Factor for Patients With Esophageal Cancer Who Receive Curative Treatment

Aoyama, Toru; Ju, Miwa; Komori, Keisuke; Tamagawa, Ayako; Onodera, Atsushi; Morita, Junya; Hashimoto, Itaru; Ishiguro, Tetsushi; Endo, Kazuya; Cho, Haruhiko; Onuma, Shizune; Fukuda, Momoko; Oshima, Takashi; Yukawa, Norio; Rino, Yasushi

doi:10.21873/invivo.12912

Cited by 6 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PLR is considered to be an accurate, easily detectable, and inexpensive marker for evaluating the prognosis of patients with NPC and guiding treatment decisions. In fact, elevated PLR levels can predict the prognosis of various tumors such as lung cancer ( Sanli et al, 2024 ), esophageal cancer ( Aoyama et al, 2022 ), and cervical cancer ( Gao et al, 2023 ).…”

Section: Discussionmentioning

confidence: 99%

Retrospective study of a novel hematological parameter for predicting the survival of patients with nasopharyngeal carcinoma

Tang,

Long

2024

PeerJ

View full text Add to dashboard Cite

Purpose This study aims to explore the prognostic values of routine pre-treatment hematological parameters in patients with nasopharyngeal carcinoma (NPC). Methods The hematological parameters and clinical data of patients with NPC were collected from January 2012 to December 2013 at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. The survival statistics were obtained by regularly following-up the patients. The cut-off values for the hematological parameters were calculated using X-tile software. SPSS version 24.0 was used for the statistical analysis. The relationship between the hematological parameters and the prognosis of patients with NPC was analyzed using the Kaplan–Meier method and Cox multivariate regression. The discriminating abilities of the factors, which predict the prognosis, were evaluated by utilizing the receiver operating characteristic (ROC) area under the curve (AUC). Results This study included 179 patients with NPC. Multivariate analysis shows that pretreatment platelet-to-lymphocyte ratio (PLR; hazard ratio; HR = 0.44, 95% CI [0.21–0.91], p = 0.029), serum albumin (ALB; HR = 2.49, 95% CI [1.17–5.30], p = 0.018), and globulin (GLO; HR = 0.44, 95% CI [0.21–0.90], p = 0.024) are independent predictors for 5-year overall survival (OS) in patients with NPC. In addition, pre-treatment PLR (HR = 0.47, 95% CI [0.25–0.90], p = 0.022) and pre-treatment GLO (HR = 0.37, 95% CI [0.19–0.72], p = 0.001) are associated with 5-year progression-free survival (PFS) in patients with NPC. Based on the results of the multivariate analysis, we proposed a new biomarker GLO-PLR, which is observably correlated with the T stage, N stage and clinical stage in patients with NPC. The OS resolving ability of the GLO-PLR evaluated by AUC is 0.714, which is better than those of GLO and PLR. The PFS resolving ability of the GLO-PLR evaluated by AUC was 0.696, which is also better than those of GLO and PLR. Conclusion Pre-treatment PLR, ALB, and GLO are independent predictors of 5-year OS in patients with NPC, where PLR and GLO are also independent predictors of 5-year FPS. Compared with other hematological parameters, the proposed GLO-PLR is an inexpensive, effective, objective, and easy-to-measure marker for predicting the prognosis of NPC.

show abstract

Section: Discussionmentioning

confidence: 99%

Retrospective study of a novel hematological parameter for predicting the survival of patients with nasopharyngeal carcinoma

Tang,

Long

2024

PeerJ

View full text Add to dashboard Cite

show abstract

“…Toru et al’s [ 34 ] study on pre-PLR in patients with esophageal cancer who received radical treatment showed that the 5-year OS rate of the low pre-PLR group was 53.8% and that of the high pre-PLR group was 38.1% ( P < .05) and that PLR was a significant prognostic factor. However, the results of the present study showed that the 5-year OS rate of patients in the high Pre-PLR group was 21.7%, and the 5-year OS rate of patients in the low Pre-PLR group was 42.1% and that surgery and other factors led to a worse prognosis.…”

Section: Discussionmentioning

confidence: 99%

Effect of dynamic platelet-to-lymphocyte ratio on the prognosis of patients with esophageal squamous cell carcinoma receiving chemoradiotherapy

He,

Du,

et al. 2023

Medicine

View full text Add to dashboard Cite

Systemic inflammatory load affects the long-term developmental outcomes in patients with malignancy. The purpose of this study was to investigate the effect of the dynamic levels of platelet-to-lymphocyte ratio (PLR) at different treatment stages on the prognosis of patients with esophageal squamous cell carcinoma (ESCC) undergoing chemoradiotherapy. This study included 168 patients who received chemoradiotherapy between 2012 and 2018. PLR levels at different treatment stages were calculated based on blood test results. The association between PLR and overall survival (OS) was determined using the Kaplan–Meier method and Cox proportional regression models. The cutoff values of PLR before and after treatment of 168 patients with ESCC were 195.7 and 403.6, respectively. The 5-year OS rates of patients in the low and high pre-PLR groups were 42.1% and 21.7%, respectively. The overall 5-year OS rate of all patients was 27.1%. Multivariate analysis results showed that patient age (hazard ratio [HR] = 1.736; 95% confidence interval (CI) = 1.129–2.669; P = .012), alcohol consumption (HR = 1.622; 95%CI = 1.050–2.508; P = .029), T stage (HR = 12.483; 95%CI = 3.719–41.896; P < .001), pre-PLR (HR = 1.716; 95%CI = 1.069–2.756; P = .025), post-PLR (HR = 1.664; 95%CI = 1.106–2.503; P = .015) were independent factors of the prognosis of patients with ESCC. PLR at different treatment stages can be used to effectively evaluate the prognosis of patients with ESCC undergoing chemoradiotherapy.

show abstract

“…Eleven studies evaluated the clinical impact of the PLR in esophageal cancer. Table IV summarizes each study (94)(95)(96)(97)(98)(99)(100)(101)(102)(103). Among them, 10 evaluated the PLR as a prognostic factor, while one study evaluated the PLR as a predictive factor for postoperative surgical complications.…”

Section: The Platelet-to-lymphocyte Ratio (Plr) In Esophageal Cancer ...mentioning

confidence: 99%

Usefulness of Nutrition and Inflammation Assessment Tools in Esophageal Cancer Treatment

Aoyama

Kazama

Maezawa

et al. 2023

In Vivo

View full text Add to dashboard Cite

Multidisciplinary treatment for esophageal cancer leads to nutritional and inflammatory changes. Recent studies showed that nutritional and inflammatory changes during multidisciplinary treatment affect both short and long-term oncological outcomes in esophageal cancer treatment. Therefore, evaluation of the nutritional and inflammatory status during treatment is necessary in order to optimize and utilize multidisciplinary therapy for esophageal cancer. If patients with esophageal cancer are able to determine their nutritional and inflammatory status, they will be able to select the optimal esophageal cancer, anti-inflammation, and nutritional treatments. Various types of nutrition and inflammation assessment tools have been developed and reported for esophageal cancer, with each tool having its own clinical characteristics, which must be understood before being applied in clinical practice. This review summarizes the background, current status, and future perspectives on the application of nutrition and inflammation assessment tools in esophageal cancer treatment.Esophageal cancer is the eighth most common type of cancer and the sixth-leading cause of cancer-related death in the world (1, 2). Curative resection and perioperative adjuvant treatment is a standard treatment for resectable esophageal cancer (3-5). Although the survival rate after surgery and adjuvant treatment is gradually increasing, almost half of all patients develop recurrent disease, even after curative treatment (6, 7).Recently, some studies have reported that the perioperative nutritional and inflammatory status affect both the short-term and long-term oncological outcomes in various malignancies (8, 9). Therefore, it is necessary to evaluate the nutritional and inflammatory status during the perioperative period in patients with esophageal cancer. If a physician can determine the nutritional and inflammatory status during treatment, they can control and manage the nutritional and inflammatory status to optimize esophageal cancer treatment. Thus far, the application of various nutritional and inflammation assessment tools, such as the Glasgow Prognostic Score (GPS), Prognostic Nutritional Index (PNI), and Controlling Nutritional Status (CONUT) have been reported in esophageal cancer (10-14). To introduce these various nutritional and inflammation assessment tools into daily clinical practice, it is necessary to understand the characteristics of each.This review summarizes the background, current status, and future perspectives of nutrition and inflammation assessment tools in esophageal cancer treatment. Search StrategyThe search strategy used in the current study was based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A literature search was performed on PubMed. The following keywords were used: "Glasgow Prognostic Score (GPS)" and "esophageal cancer (or carcinoma)"; "Prognostic Nutritional Index" and "esophageal cancer (or carcinoma)"; "Controlling Nutritional Status" and "esophageal cancer (or carcin...

show abstract

The Platelet-to-Lymphocyte Ratio Is an Independent Prognostic Factor for Patients With Esophageal Cancer Who Receive Curative Treatment

Cited by 6 publications

References 20 publications

Retrospective study of a novel hematological parameter for predicting the survival of patients with nasopharyngeal carcinoma

Retrospective study of a novel hematological parameter for predicting the survival of patients with nasopharyngeal carcinoma

Effect of dynamic platelet-to-lymphocyte ratio on the prognosis of patients with esophageal squamous cell carcinoma receiving chemoradiotherapy

Usefulness of Nutrition and Inflammation Assessment Tools in Esophageal Cancer Treatment

Contact Info

Product

Resources

About